Investigational drug · Phase 3
Dersimelagon
Also called: MT-7117
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for EPP, XLP, Erythropoietic Protoporphyria (EPP).
Phase 3Last checked: Nov 20, 2026Latest source record: Sep 9, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
7
Any phase or sponsor naming "Dersimelagon"
First trial start
2021
Aug 10, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Dersimelagon", any sponsor or status.
Conditions studied
As listed on its trial records.
- EPP
- XLP
- Erythropoietic Protoporphyria (EPP)
- X-Linked Protoporphyria (XLP)
Approved drugs for the same conditions: Hematology and blood cancers · Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "Dersimelagon" as an intervention, largest first.
- Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)Pivotal-lookingActive, not recruiting
Tanabe Pharma America, Inc.Industry
NCT05005975 · 286 participants · Start Aug 10, 2021 · Primary completion Dec 2027
Drug: MT-7117 · For: EPP; XLP
Sites: Huntington Beach, California; San Francisco, California; Miami, Florida · 45 sites in all
- Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Erythropoietic Protoporphyria or X-Linked ProtoporphyriaPivotal-lookingCompleted
Tanabe Pharma America, Inc.Industry
NCT04402489 · 184 participants · Start Jun 1, 2020 · Primary completion Dec 14, 2021
Drug: Placebo; MT-7117 Low Dose and 1 more · For: EPP; XLP
Sites: Huntington Beach, California; Miami, Florida; Brighton, Massachusetts · 31 sites in all
- INcreased Sun Exposure Without Pain In Research Participants With EPP or XLPPivotal-lookingCompleted
Tanabe Pharma America, Inc.Industry
NCT06144840 · 165 participants · Start Dec 11, 2023 · Primary completion Apr 14, 2026
Drug: Dersimelagon; Placebo · For: Erythropoietic Protoporphyria (EPP); X-Linked Protoporphyria (XLP)
Sites: Huntington Beach, California; San Francisco, California; Miami, Florida · 35 sites in all
- Study to Investigate Drug-Drug Interaction Between MT-7117 and Test Drugs in Healthy SubjectsCompleted
Tanabe Pharma America, Inc.Industry
NCT04793295 · 112 participants · Start Mar 23, 2021 · Primary completion Feb 4, 2022
Drug: MT-7117 · For: Healthy Subjects
Sites: Miami, Florida; San Antonio, Texas
Tanabe Pharma America, Inc.Industry
NCT04440592 · 76 participants · Start Feb 5, 2021 · Primary completion Jan 17, 2024
Drug: MT-7117; Placebo · For: Diffuse Cutaneous Systemic Sclerosis
Sites: Glendale, Arizona; Los Angeles, California; Redwood City, California · 34 sites in all
Tanabe Pharma CorporationIndustry
NCT06994286 · 40 participants · Start Jun 24, 2025 · Primary completion Jul 21, 2025
Drug: MT-7117; Placebo · For: Healthy Subjects
Sites: Beijing, China
Tanabe Pharma America, Inc.Industry
NCT04656795 · 32 participants · Start Dec 2, 2020 · Primary completion Dec 4, 2021
Drug: MT-7117 · For: Renal Impairment; Normal Renal Function
Sites: Kiel, Germany
Newest research
PubMed records naming it or its code names, newest first.
- Study Design and Baseline Characteristics of APOLLO: A Phase 3 Study of Bitopertin in Erythropoietic Protoporphyria and X-Linked Protoporphyria.
Yeung A, Amster M, Anderson KE, et al. · J Dermatol 2026
- Endocrine Modulation of Inflammation: The Role of Adrenocorticotropic Hormone and Cortisol.
Vidal M, Lane NE · Endocr Pract 2026
- New and currently investigated pharmacotherapies for the erythropoietic protoporphyrias: spotlight on dersimelagon and bitopertin.
Barman-Aksözen J, Granata F, Wäscher S, et al. · Expert Opin Pharmacother 2026
- New pharmacotherapies for the erythropoietic protoporphyrias: an analysis of trial protocols from a patient perspective.
Dechant C, Wäscher S, Granata F, et al. · Orphanet J Rare Dis 2025
- Polymorphism of Melanocortin Receptor Genes-Association with Inflammatory Traits and Diseases.
Bardhan M, Anand A, Javed A, et al. · Diseases 2025
- Assessment of Potential Drug-Drug Interactions for Novel Oral Melanocortin-1 Receptor Agonist Dersimelagon.
Ogasawara A, Ide R, Inoue S, et al. · Pharmacol Res Perspect 2025
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.